Climb Bio rises as FDA grants fast-track status to kidney disease drug

Climb Bio

07/04/2026 12:48

** Shares of biotech firm Climb Bio CLYM.O rise 3.7% to $6.99 premarket

** Co says the U.S. FDA has granted fast-track designation to its experimental drug, budoprutug, for primary membranous nephropathy, a rare kidney disease with no FDA-approved treatments

** Fast-track status is meant to speed development and review of treatments for serious diseases with unmet medical needs

** Co says in an early-stage study, the drug removed the disease-driving B cells in all five patients, improved disease-related antibody levels in all three evaluable patients, and led to complete or partial remission of the disease in all patients by week 48

** Says the drug is now being tested in a mid-stage global study, with initial data expected in the second half of 2026

** As of last close, stock up 68.5% YTD

 (Reporting by Kunal Das in Bengaluru)

 ((Kunal.Das2@thomsonreuters.com;))